Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neurofibroma × mirdametinib × Clear all

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Neurofibromatosis 1 1 Neurofibroma 1 KRAS Mutant Non-Small Cell Lung Cancer 1 Breast Neoplasms 1

Interventions

tipifarnib 1 peginterferon alfa-2b 1 nilotinib 1 mirdametinib 1 binimetinib 1 Vincristine 1 Temozolomide 1 Sirolimus 1 Ranibizumab 1 Radiosurgery 1 Mn-PyC3A 1 Imatinib Mesylate 1 Everolimus 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02096471 2019-01-10

MEK Inhibitor

University of Alabama at Birmingham

Phase 2 Completed

19 enrolled 14 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡